C12N 2740/16171
Demonstrated in vivo effect
C12N2740/16171 (Demonstrated in vivo effect) appears on 77 US grants and 111 published applications in this corpus.
Search patents in C12N- Granted patents
- 77
- Published applications
- 111
- Assignees
- 68
- Inventors
- 178
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 1 | 2 |
| 2007 | 1 | 2 |
| 2008 | 0 | 6 |
| 2009 | 1 | 4 |
| 2010 | 2 | 0 |
| 2011 | 3 | 3 |
| 2012 | 2 | 7 |
| 2013 | 2 | 2 |
| 2014 | 0 | 5 |
| 2015 | 4 | 5 |
| 2016 | 6 | 18 |
| 2017 | 8 | 12 |
| 2018 | 8 | 6 |
| 2019 | 10 | 9 |
| 2020 | 9 | 10 |
| 2021 | 4 | 5 |
| 2022 | 9 | 2 |
| 2023 | 1 | 3 |
| 2024 | 3 | 4 |
| 2025 | 1 | 1 |
| 2026 | 2 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Modified envelope protein of human immunodeficiency virus and use thereof4 Aug 2026US 12,697,383 B2Xiamen Innovax Biotech Co., Ltd.
- HIV-1 ENV fusion peptide immunogens and their use4 Nov 2025US 12,458,691 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Glycan-masked engineered outer domains of HIV-1 gp120 and their use6 Aug 2024US 12,053,520 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins13 Feb 2024US 11,896,663 B2Janssen Vaccines & Prevention B. V.
- Hiv immunogens and methods of using same23 Jul 2026US 2026/0207733 A1The Wistar Institute of Anatomy and Biology
- Ch505 envelopes to engage and mature cd4 binding site neutralizing antibodies4 Jun 2026US 2026/0151474 A1
- Hiv-1 env fusion peptide immunogens and their use28 May 2026US 2026/0144860 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Ch505 envelopes to engage and mature cd4 binding site neutralizing antibodies29 Jan 2026US 2026/0028376 A1
- Compositions and methods for treating or preventing hiv infection6 Mar 2025US 2025/0073328 A1
Most cited
By later US patents
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Albumin fusion proteins96US 7,592,010 B2Delta Biotechnology Limited · 2009
- Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen63US 8,454,972 B2GenVec, Inc. · 2013
- Antiviral vaccines with improved cellular immunogenicity48US 9,017,691 B2Beth Israel Deaconess Medical Center, Inc. · 2015
- Albumin fusion proteins34US 7,847,079 B2Human Genome Sciences, Inc. · 2010